Overview

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

Status:
Recruiting

Trial end date:
2024-12-31

Target enrollment:
0

Participant gender:
Female

Summary

To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Mackay Memorial Hospital

Treatments:

Estrogens
Solifenacin Succinate

Criteria

Inclusion Criteria:

- Patients with detrusor overactivity which defined as a urodynamic observation
characterized by involuntary detrusor contractions during the filling phase. Those who
were refractory to monotherapy with anti-muscarinics were enrolled for prospective
study.

Exclusion Criteria:

- Postvoid urine retention before treatment

- Women who had medical illness and contraindication for using solifenacin and
mirabegron, such as narrow-angle glaucoma and hypertension

- Concerns for using estrogen include: Women with history of cerebrovascular disease;
thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma;
estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.

- Women who were on hormone replacement therapy within 3 months were also excluded from
the study